Docket No.

000364.00124

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Juerg Lareida

SERIAL NO:

Unknown

GAU:

FILED: Concurrenty Herewith

EXAMINER:

FOR:

Medicament for Treatment of Neuropathies

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

\boxtimes	The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies
	of the listed references are attached, where required, as are either statements of relevancy or any readily
	available English translations of pertinent portions of any non-English language references.
П	A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a copy of applicant's pending application(s) or issued patent(s) which may be related to the present application. These documents are listed on form PTO-1449, also attached.

A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited for the first time in П any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

 \boxtimes This Information Disclosure Statement is being filed within three months of the filing date of the subject patent application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

PETITION

 \boxtimes

Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR §1.17(i)(1).

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

BLANK ROME COMISKY & MCCAULEY LLP

THE FARRAGUT BUILDING SUITE 1000 900 17TH STREET, NW WASHINGTON, DC 20006 TEL (202) 530-7400 FAX (202) 463-6915

27557

Date: March 15, 2002

Merbert Cohen Attorney of Record Registration No. 25,109



10/088113 Rec'd PCT/PTO 15 MAR 2002 SERIAL NO. Unknown

ATTY. DOCKET NO. 000364.00124

Form PTO 1449 (Modified) U.S. DEFERRANCE PATENT AND TRADEMARK OFFICE PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO. Unknown					
					APPLICANT Juerg Lareida FILING DATE Concurrently Herewith					
C 111					U.S.	PATENT DOCUMENTO	CLASS	SUB	FILI	DODDIATE
XAMINER		DO	OC. NUMBER	DATE		NAME	514	CLASS 229	IF APF	ROPRIATE
INITIAL	1	4 666	3 908	1987	Ham	ilton	514	258	1	
	AA 4,666,908 AB 6,075,028		2000 Gr		nam		+			
		0,01	3,0 ==	1	1			+-/-		-
	AC	┼			1			1/-	_	
	AD	 		+	1					
	AE						//	4	_	
	AF				\dashv					
	AG						- M			
	Al	1		_			W			
	Α	<u> </u>				į	<u> </u>			
	A.	J			-+	P				
	A	ĸ 📗				w/				
	A	L			-+	DAM				
	A	M								
	A	N				REIGN PATENT DOCUMENTS	3		TRANS	_ATION
				R I DA		COUNTRY	,		ES	<u>NO</u>
	_	1	DOC. NUMBE	`` \						
	y 1	AO M	VO 93/07149	19	93	VIPO /				
		AP								
		AQ								
		AR				/				
		AS			$\overline{}$					
	}				7					
		AU								
				-/			to Portinen	t Pages, et	c.)	
	l		OTHER R	EFEREN	CES (Including Author, Title, D Itment of Erectile Dysfuncti Association, Vol. 281, No.	ale, Fertinon	th Diahetes.	XP-0009	86570 - JAMA,
			To-adoll at al. &	ildenafil fo	r Trea	tment of Erectile Dysfuncti	on in ivien wi 5. 1999			h Darkinson's
	7	AW	TIATIONAL OF ME / 1					•		
		AX	Zesiewicz et al.	, Sidenafil	Citrat	ology, Bd. 52, Nr. 6, 1999	la Diagos	e XP-00099	91091 - M	ovement
	AW Rendell et al., Sildenafil for Treatment of Erectile Dystunction Journal of the Americal Medical Association, Vol. 281, No. 5, 1999 Journal of the Americal Medical Association, Vol. 281, No. 5, 1999 AX Zesiewicz et al., Sidenafil Citrate (Viagra) for the Treatment of Erectile Dysfunction in Men with Parkinson Disease, XP-000989552- Neorology, Bd. 52, Nr. 6, 1999 Disease, XP-000989552- Neorology, Bd. 52, Nr. 6, 1999 AY Brewer et al., Sildenafil Citrate Therapy in Men with Parkinson's Disease, XP-000991091 - Movement Disorders, Bd. 13, Nr. 5, 1998 AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AND Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AND Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Sildenafil for latrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction AZ Numberg et al., Silden									
	5	AY	ID:Aardare DO	13. 141. 9		- Language April	ייי אוופססמווי			
		AZ	Nurnberg et al.	, Sildenafi	i for la	trogenic Serotenergic And rnal of Clinical Psychiatry, ort: Use of Sildenafil to Trea d. 54, Nr. 7, 2000	Nd. 60. Nr. 1,	, 1999 s in Patients	with Park	inson's Disease
	+		4 Patients, Sr		. Don	orth Use of Sildenami to Tree	it Dyon			
1		XAZZ	SP-002162785	5 - Neurolo	gy, B	not citation is in conformance	· ·	Date Consid	lered	is not in
1	4									

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.